Macular pigment analyser Австралия - английский - Department of Health (Therapeutic Goods Administration)

macular pigment analyser

france medical pty ltd -

ACULAR 0,5% Topical Ophthalmic Solution ЮАР - английский - South African Health Products Regulatory Authority (SAHPRA)

acular 0,5% topical ophthalmic solution

allergan -

ACULAR 0.5% col·liri solució 5 ml Андорра - английский - CedimCat (Centre d'Informació de Medicaments de Catalunya)

acular 0.5% col·liri solució 5 ml

ACULAR GERVASI 0.5% col·liri solució 5 ml Андорра - английский - CedimCat (Centre d'Informació de Medicaments de Catalunya)

acular gervasi 0.5% col·liri solució 5 ml

JETREA RTU ocriplasmin (ryp) 0.375 mg/0.3 mL solution for intravitreal injection vial Австралия - английский - Department of Health (Therapeutic Goods Administration)

jetrea rtu ocriplasmin (ryp) 0.375 mg/0.3 ml solution for intravitreal injection vial

i-care pharma distributors pty ltd - ocriplasmin, quantity: 1.25 mg/ml - injection, solution - excipient ingredients: mannitol; citric acid monohydrate; sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - jetrea rtu is indicated in adults for the treatment of vitreomacular traction (vmt), including when associated with macular hole of diameter less than or equal to 400 microns.

EYLEA Израиль - английский - Ministry of Health

eylea

bayer israel ltd - aflibercept - solution for intravitreal injection - aflibercept 40 mg/ml - aflibercept - eylea is indicated for adults for the treatment of • neovascular (wet) age-related macular degeneration (amd)• visual impairment due to macular oedema secondary to retinal vein occlusion (branch crvo or central rvo)• visual impairment due to diabetic macular oedema (dme)• visual impairment due to myopic choroidal neovascularisation (myopic cnv).

Vabysmo Европейский союз - английский - EMA (European Medicines Agency)

vabysmo

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - ophthalmologicals - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Beovu Европейский союз - английский - EMA (European Medicines Agency)

beovu

novartis europharm limited  - brolucizumab - wet macular degeneration - ophthalmologicals - beovu is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (amd).

BEOVU brolucizumab (rbe) 120 mg/mL solution for injection in vial Австралия - английский - Department of Health (Therapeutic Goods Administration)

beovu brolucizumab (rbe) 120 mg/ml solution for injection in vial

novartis pharmaceuticals australia pty ltd - brolucizumab, quantity: 120 mg/ml - injection, solution - excipient ingredients: sodium citrate; sucrose; polysorbate 80; water for injections - beovu is indicated for the treatment of: - neovascular (wet) age-related macular degeneration (amd). - diabetic macular oedema (dme)

MaQaid OPHTHALMIC INJECTION 40mg [reduction of macular edema complicated with diabetic macular edema] (マキュエイド眼注用40mg［糖尿病黄斑浮腫に伴う黄斑浮腫の軽減］) Япония - английский - すりの適正使用協議会 RAD-AR Council, Japan

maqaid ophthalmic injection 40mg [reduction of macular edema complicated with diabetic macular edema] (マキュエイド眼注用40mg［糖尿病黄斑浮腫に伴う黄斑浮腫の軽減］)

wakamoto pharmaceutical co., ltd - triamcinolone acetonide - injection